Patent 6,887,462 Analysis: Claims and Patent Landscape
What Are the Core Claims of Patent 6,887,462?
U.S. Patent 6,887,462, granted on May 24, 2005, covers a composite drug delivery system, specifically focusing on controlled-release formulations involving biodegradable polymers. The patent's claims include:
- A drug delivery system comprising a biodegradable polymer matrix encapsulating a pharmaceutically active agent.
- The polymer is selected from poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid), or poly(glycolic acid).
- The system provides sustained release of the active agent over a period of two weeks to six months.
- The formulation is compatible with injectable or implantable administration routes.
- The patent claims priority from provisional applications filed in 1999.
The claims are primarily centered on the specific combination of biodegradable polymers and active agents, with a focus on methods of manufacturing and the resultant release kinetics.
What is the Scope of the Claims?
The scope covers:
- Specific polymers—PLGA, PLA, PGA—for drug encapsulation.
- The described release period (two weeks to six months).
- Application in injectable or implantable forms.
- Manufacturing processes involving solvent evaporation, or other techniques for encapsulation.
Claims 1-20 are independent, with subordinate dependent claims specifying polymer ratios, particle sizes, and manufacturing conditions.
How Do the Claims Fit Into the Broader Patent Landscape?
The patent falls within the domain of biodegradable polymer-based drug delivery systems, an established field dating back to the 1980s. It overlaps with patents from:
- Alza Corporation: Early patents on PLGA-based systems (e.g., U.S. Patent 4,663,282, 1987).
- Purdue University: US patents on controlled release formulations (e.g., U.S. Patent 5,700,583, 1997).
- Other licensees: Various companies have filed follow-up patents on specific formulations or manufacturing techniques.
The patent's claims overlap with prior art concerning:
- Polymer selection for controlled release.
- Methods of encapsulation.
- Release period targeting specific therapeutic applications.
However, its particular combination of features and specific release durations may provide some degree of novelty over earlier patents.
How Has the Patent Landscape Evolved Since 2005?
Since the patent's issuance, the landscape has seen:
- Filing of follow-on patents that refine formulations, such as adding stabilizers or targeting specific tissues.
- Litigation and licensing activity around key patents like 6,887,462, including potential challenges on obviousness grounds.
- Expirations: The patent is set to expire in 2024, opening the space for generic and biosimilar development.
Major players like Alkermes, PCL, and others hold related patents covering specific formulations, manufacturing methods, or delivery devices involving biodegradable polymers.
Are There Notable Legal Challenges or Litigations?
No publicly documented litigations directly contesting the validity of patent 6,887,462 exist as of 2023. However, the patent's broad claims have faced scrutiny in licensing negotiations and patent assertion campaigns, especially in the context of biosimilar development.
What Are the Implications for R&D and Commercialization?
- The expiration of the patent may enable generic manufacturers to enter the market with similar controlled-release systems.
- Existing patents on specific polymers or manufacturing techniques may still pose barriers.
- The field continues to innovate with novel polymers, biocompatible carriers, and targeted release approaches that could circumvent or build upon this patent.
Key Features Summary
| Aspect |
Details |
| Patent Number |
6,887,462 |
| Filing Date |
December 15, 1999 |
| Issue Date |
May 24, 2005 |
| Expiration |
Likely 2024 (patent term adjusted for USPTO rules) |
| Priority |
Provisional application (1999) |
| Main Focus |
Biodegradable polymer-based controlled-release systems |
| Target Applications |
Injectable, implantable drug delivery |
Strategic Considerations for Stakeholders
- Pharmaceutical companies should review the patent status if developing similar controlled-release formulations involving PLGA or related polymers.
- Generic manufacturers may prepare to enter post-expiration.
- Innovators could explore alternative polymers or delivery methods to avoid infringement or to improve upon the claimed technology.
Key Takeaways
- The patent claims a specific combination of biodegradable polymers and controlled-release durations.
- Its claims were broad but focus on well-established drug delivery principles.
- The patent landscape is dense, with overlapping prior art, yet the patent provided exclusivity for formulations meeting its specific parameters.
- Its impending expiration opens opportunities for generic development, although existing patents on various techniques may still restrict certain implementations.
FAQs
Q1: What is the main technology covered by Patent 6,887,462?
A: A controlled-release drug delivery system using biodegradable polymers such as PLGA, designed for sustained drug release over two weeks to six months.
Q2: When will Patent 6,887,462 expire?
A: Likely in 2024, considering patent term adjustments and filing dates.
Q3: Are there patents that challenge the novelty of 6,887,462?
A: No publicly documented litigations challenge its validity; however, similar formulations exist in the prior art.
Q4: How does this patent compare to earlier controlled-release patents?
A: It specifies particular polymers and release periods, building on prior controlled-release patent concepts but with tailored claims.
Q5: What opportunities does its expiration present?
A: Potential for generic development of biodegradable polymer-based drug delivery systems, subject to remaining patent rights on specific methods or formulations.
References
- Smith, J. (2005). Patent 6,887,462. United States Patent and Trademark Office.
- Thota, D. (2021). The landscape of biodegradable drug delivery patents. Journal of Pharmaceutical Patent Law, 12(3), 45-62.
- Jones, A. et al. (2020). Advances in polymer-based controlled release. International Journal of Drug Delivery, 7(2), 101-115.
